Prevention of dialysate-induced peritoneal damage by pyridoxal phosphate
Not Applicable
- Conditions
- Patients with end-stage renal disease on peritoneal dialysis
- Registration Number
- JPRN-UMIN000001287
- Lead Sponsor
- Miyanomori Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1, Patients with heart failure of NYHAIII and IV
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method After starting PLP treatment, the concentrations of growth factors, chemical mediators and AGE in used dialysate will be regularly measured and those indices will be compared between dialysate before and after PLP treatment.
- Secondary Outcome Measures
Name Time Method An appropriate daily dosage of PLP will be determined.